Limits...
Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention

View Article: PubMed Central - PubMed

ABSTRACT

Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are 2 rare autoimmune disorders which commonly affect women. Several previous studies showed APS to have been evolved from SLE. Secondary APS often coexists with SLE. One common feature relating these 2 diseases are the antiphospholipid antibodies, which are found in most of the patients with APS and in approximately 30% to 40% of patients with SLE, among which, about 10% develop APS. The leading cause of death in these patients is from cardiovascular disease due to accelerated atherosclerosis, which often progresses more rapidly, compared with the general population. However, the impact of APS and/or SLE on the cardiovascular outcomes in patients undergoing percutaneous coronary intervention (PCI) is controversial. Therefore, to solve this issue, we aim to compare the long-term (≥1 year) adverse cardiovascular outcomes after PCI, in patients with APS and/or SLE, and those without these disorders.

Medline and EMBASE databases were searched for studies comparing the long-term adverse cardiovascular outcomes between SLE and non-SLE, APS and non-APS, or SLE + APS and non-SLE + non-APS after PCI. We calculated odd ratios (OR) and 95% confidence intervals (CIs) for these categorical variables, and the pooled analyses were performed with RevMan 5.3.

Seven studies consisting of a total of 253,436 patients (568 patients in the experimental group and 252,868 patients in the control group) were included in this meta-analysis. During a follow-up period of ≥1 year, mortality and myocardial Infarction (MI) were significantly higher in the experimental group (OR 2.02, 95% CI 1.63–2.49, P < 0.00001 and OR 1.59, 95% CI 1.23–2.05, P = 0.0004, respectively). Major adverse cardiac events and repeated revascularization were also significantly higher in the SLE/APS group (OR 2.40, 95% CI 1.42–4.03, P = 0.001 and OR 2.59, 95% CI 1.26–5.31, P = 0.01, respectively).

Antiphospholipid syndrome and SLE are associated with significantly higher long-term (≥1 year) adverse cardiovascular outcomes after PCI. However, because of the limited number of patients and researches done, and due to a larger percentage of heterogeneity observed among several subgroups, this analysis may not generate a powerful result.

No MeSH data available.


Related in: MedlinePlus

Forest plot showing the long-term results for major adverse cardiac events and repeated revascularization between the SLE/APS group and the control group after PCI. APS = antiphospholipid syndrome, PCI = percutaneous coronary intervention, SLE = systemic lupus erythematosus.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998416&req=5

Figure 3: Forest plot showing the long-term results for major adverse cardiac events and repeated revascularization between the SLE/APS group and the control group after PCI. APS = antiphospholipid syndrome, PCI = percutaneous coronary intervention, SLE = systemic lupus erythematosus.

Mentions: Since a higher heterogeneity was observed when calculating the OR for MACEs and repeated revascularization, a random-effect model was used. MACEs were significantly higher in the experimental group (OR 2.40, 95% CI 1.42–4.03, P = 0.001). Repeated revascularization was also significantly higher in the experimental group (OR 2.59, 95% CI 1.26–5.31, P = 0.01). This result has been shown in Figure 3. Table 4 shows the detailed overall results obtained when comparing the adverse cardiovascular outcomes between patients with SLE/APS and non-SLE/non-APS after PCI.


Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention
Forest plot showing the long-term results for major adverse cardiac events and repeated revascularization between the SLE/APS group and the control group after PCI. APS = antiphospholipid syndrome, PCI = percutaneous coronary intervention, SLE = systemic lupus erythematosus.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998416&req=5

Figure 3: Forest plot showing the long-term results for major adverse cardiac events and repeated revascularization between the SLE/APS group and the control group after PCI. APS = antiphospholipid syndrome, PCI = percutaneous coronary intervention, SLE = systemic lupus erythematosus.
Mentions: Since a higher heterogeneity was observed when calculating the OR for MACEs and repeated revascularization, a random-effect model was used. MACEs were significantly higher in the experimental group (OR 2.40, 95% CI 1.42–4.03, P = 0.001). Repeated revascularization was also significantly higher in the experimental group (OR 2.59, 95% CI 1.26–5.31, P = 0.01). This result has been shown in Figure 3. Table 4 shows the detailed overall results obtained when comparing the adverse cardiovascular outcomes between patients with SLE/APS and non-SLE/non-APS after PCI.

View Article: PubMed Central - PubMed

ABSTRACT

Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are 2 rare autoimmune disorders which commonly affect women. Several previous studies showed APS to have been evolved from SLE. Secondary APS often coexists with SLE. One common feature relating these 2 diseases are the antiphospholipid antibodies, which are found in most of the patients with APS and in approximately 30% to 40% of patients with SLE, among which, about 10% develop APS. The leading cause of death in these patients is from cardiovascular disease due to accelerated atherosclerosis, which often progresses more rapidly, compared with the general population. However, the impact of APS and/or SLE on the cardiovascular outcomes in patients undergoing percutaneous coronary intervention (PCI) is controversial. Therefore, to solve this issue, we aim to compare the long-term (≥1 year) adverse cardiovascular outcomes after PCI, in patients with APS and/or SLE, and those without these disorders.

Medline and EMBASE databases were searched for studies comparing the long-term adverse cardiovascular outcomes between SLE and non-SLE, APS and non-APS, or SLE + APS and non-SLE + non-APS after PCI. We calculated odd ratios (OR) and 95% confidence intervals (CIs) for these categorical variables, and the pooled analyses were performed with RevMan 5.3.

Seven studies consisting of a total of 253,436 patients (568 patients in the experimental group and 252,868 patients in the control group) were included in this meta-analysis. During a follow-up period of ≥1 year, mortality and myocardial Infarction (MI) were significantly higher in the experimental group (OR 2.02, 95% CI 1.63–2.49, P < 0.00001 and OR 1.59, 95% CI 1.23–2.05, P = 0.0004, respectively). Major adverse cardiac events and repeated revascularization were also significantly higher in the SLE/APS group (OR 2.40, 95% CI 1.42–4.03, P = 0.001 and OR 2.59, 95% CI 1.26–5.31, P = 0.01, respectively).

Antiphospholipid syndrome and SLE are associated with significantly higher long-term (≥1 year) adverse cardiovascular outcomes after PCI. However, because of the limited number of patients and researches done, and due to a larger percentage of heterogeneity observed among several subgroups, this analysis may not generate a powerful result.

No MeSH data available.


Related in: MedlinePlus